Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-736-8 | CAS number: 149-30-4
Epidemiological data
Administrative data
- Endpoint:
- epidemiological data
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: acceptable, well-documented publication which meets basic scientific principles
Data source
Reference
- Reference Type:
- publication
- Title:
- Cancer risk in chemical production workers exposed to 2-mercaptobenzothiazole
- Author:
- Sorahan, T.
- Year:
- 2 009
- Bibliographic source:
- Occup. Environ. Med. 66, 269-273
Materials and methods
- Study type:
- cohort study (retrospective)
- Endpoint addressed:
- carcinogenicity
- Principles of method if other than guideline:
- other: investigation of cancer risk in chemical production workers
- GLP compliance:
- no
Test material
- Reference substance name:
- Benzothiazole-2-thiol
- EC Number:
- 205-736-8
- EC Name:
- Benzothiazole-2-thiol
- Cas Number:
- 149-30-4
- Molecular formula:
- C7H5NS2
- IUPAC Name:
- 1,3-benzothiazole-2-thiol
- Details on test material:
- 2-mercaptobenzothiazole
Constituent 1
Method
- Details on study design:
- The mortality (1955 to 2005) and cancer morbidity experience (1971 to 2005) of a cohort of 363 male production workers exposed to MBT while employed at a chemical in north Wales were investigated. Two analytical approaches were used, indirect standardisation and Poisson regression.
- Exposure assessment:
- estimated
Results and discussion
- Results:
- Limited findings
Any other information on results incl. tables
Based on national mortality rates, significant excess mortality was found for cancers of the large intestine and bladder. Non-significant excesses were shown for lung cancer and multiple myeloma. Based on national cancer incidence rates, significant excess morbidity was found for cancer of the bladder and multiple myeloma. Non-significant excesses were shown for cancers of the large intestine and lung. In analyses that included follow-up information on an additional 1797 plant employees not exposed to MBT, Poisson regression showed significant positive trends both for risks of cancer of the large intestine and for risks of multiple myeloma in relation to estimated cumulative exposure to MBT. The authors concluded that MBT may be a human carcinogen.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
